



LKT Laboratories, Inc.

XL-765

Phone: 888-558-5227  
651-644-8424  
Fax: 888-558-7329  
Email: [getinfo@lktlabs.com](mailto:getinfo@lktlabs.com)  
Web: [lktlabs.com](http://lktlabs.com)

## Product Information

Product ID X4424

CAS No. 934493-76-2

### Chemical Name

Synonym XL765, Voxtalisisb, SAR245409

Formula  $C_{13}H_{14}N_6O$

Formula Wt. 270.29

### Melting Point


Purity  $\geq 98\%$

Solubility DMSO 12 mg/mL (20.01 mM)  
Water Insoluble  
Ethanol Insoluble

Store Temp  $-20^{\circ}C$

Ship Temp Ambient

**Description** XL-765 is an inhibitor of PI3K and mTOR that displays anticancer chemotherapeutic and anti-angiogenic activities; it is currently in clinical trials as a potential treatment for lymphomas and solid tumors. XL-765 inhibits cell proliferation, tumor growth, and angiogenesis in cellular and animal models of cancers.



## Pricing and Availability

*Bulk quantities available upon request*

Product ID	Size	List Price
X4424	1 mg	\$108.00
X4424	5 mg	\$183.30
X4424	10 mg	\$297.30

**References** Papadopoulos KP, Egile C, Ruiz-Soto R, et al. Efficacy, safety, pharmacokinetics and pharmacodynamics of SAR245409 (voxtalisib, XL765), an orally administered phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor: a phase 1 expansion cohort in patients with relapsed or refractory lymphoma. *Leuk Lymphoma*. 2014 Nov 19:1-8. [Epub ahead of print] PMID: 25300944.

Yu P, Laird AD, Du X, et al. Characterization of the activity of the PI3K/mTOR inhibitor XL765 (SAR245409) in tumor models with diverse genetic alterations affecting the PI3K pathway. *Mol Cancer Ther*. 2014 May;13(5):1078-91. PMID: 24634413.

Papadopoulos KP, Tabernero J, Markman B, et al. Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumors. *Clin Cancer Res*. 2014 May 1;20(9):2445-56. PMID: 24583798.

**Caution:** This product is intended for laboratory and research use only. It is not for human or drug use.